-
EC eCQMs - Eligible Clinicians
-
Resolution: Answered
-
Moderate
-
None
-
None
-
Esperanza Health Centers
-
-
CMS0117v12
-
CMS0117v11
-
Substantial impact on our performance rate on the measure
Per the Updated Recommendations of the Advisory Committee on Immunization Practices published July 2023, our health center (and VFC program) has transitioned to the 20-valent pneumococcal conjugate vaccine (PCV20) for children. However, PCV20 is not included in the eCQM Update 2023-05-04 version of the Pneumococcal Conjugate Vaccine value set used for CMS117v12; it is only included in the latest value set.
As a Federally Qualified Health Center, we are required to report CMS117 as part of the Uniform Data System. If held strictly to CMS117v12 and eCQM Update 2023-05-04 for this value set, we will not be able to satisfy the measure in the 2024 Performance Period for any children who received any number of PCV20 doses for their 4-dose series (a substantial impact). Note that this also poses a problem for Performance Period 2023, though the impact is much smaller due to most pneumococcal vaccine series being completed for eligible patients prior to the updated recommendations for PCV20.
- relates to
-
EKI-27 CMS117v11 and CMS117v12
- To Do